The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The occurrence of grade 4 adverse events and survival outcomes in patients with nonsquamous non-small cell lung cancer receiving bevacizumab with chemotherapy in the phase III PointBreak and AVAiL studies.
Liza Cosca Villaruz
No relevant relationships to disclose
Mark A. Socinski
Honoraria - Lilly
Research Funding - Lilly
Jyoti D. Patel
No relevant relationships to disclose
Larry Leon
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Sebastien Hazard
Employment or Leadership Position - Genentech
Stock Ownership - Roche
Martin Reck
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche/Genentech